Skip Navigation

JNCI Journal of the National Cancer Institute 1992 84(11):887-892; doi:10.1093/jnci/84.11.887
© 1992 by Oxford University Press
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Ornitz, D. M.
Right arrow Articles by Leder, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ornitz, D. M.
Right arrow Articles by Leder, P.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 84, No. 11, 887-892, June 3, 1992
© 1992 Oxford University Press

Int-2, an Autocrine and/or Ultra—Short-Range Effector in Transgenic Mammary Tissue Transplants

David M. Ornitz*,, Robert D. Cardiff, Ann Kuo, Philip Leder

Howard Hughes Medical Institute and Department of Genetics, Harvard Medical School Boston, Mass
Department of Pathology, School of Medicine, University of California Davis

*Correspondence to present address: David M. Ornitz, M.D., Ph.D., Department of Molecular Biology and Pharmacology, Washington University School of Medicine, 660 S. Euclid St., Box 8103, St. Louis, MO 63110.

Background: Previous studies have shown associations between over-expresion of int-2 messenger RNA (mRNA) and murine mammary tumors and between amplification of the int-2 genomic locus and human breast cancers. The Int-2 protein (fibroblast growth factor 3) is a member of the heparin-binding growth factor family of proteins. The export of these growth factors from cells may depend on the presence of amino terminal sequences containing hydrophobic signal peptides. Although Int-w has a putative signal sequence, it is not known whether or how this protein is secreted from cells. Purpose: Assuming that the Int-2 protein is secreted from mammary epithelial cells in a basolateral direction so that it is available to affect adjacent cells, we investigated whether it acts in a paracrine manner, exerting its effect externally on adjacent cells, or in an autocrine manner, exerting its effect internally within the same cell. Methods: Using in situ hybridization with 35S-labeled RNA antisense probes that specifically detect mRNA coding for the Int-2 protein, we determined the cell-specific localization of int-2 mRNA expression in the mammary gland of transgenic FVB/N mice overexpressing int-2 mRNA. Then we transplanted pieces of mammary epithelial tissue expressing int-2 mRNA into the mammary fat-pad of wild-type, syngeneic animals. The mammary glands of host animals were examined as whole-mounts and as histologic sections 2–6 months after transplantation. In situ hybridization was used to confirm which cells continued to express int-2 mRNA following transplantation. Results: Int-2 mRNA expression in transgenic mice was localized to the mammary epithelial cells. Transplants expressing int-2 mRNA were similar to wild-type transplants in that they had no observable effect on either the growth or the morphology of host mammary epithelium. Abnormal growth occurred only in transplanted tissue expressing int-2 mRNA but not in adjacent host mammary epithelium. Conclusion: Given the limitations of our experimental system and the limited information available to date on the secretion of Int-2 protein, these results suggest that, although the Int-2 protein contains a putative signal pep-tide, it may act primarily as an autocrine or as an ultra—short-range paracrine growth factor in mammary epithelium. [J Natl Cancer Inst 84: 887–892, 1992]



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Cancer Res.Home page
C. Cadieux, S. Fournier, A. C. Peterson, C. Bedard, B. J. Bedell, and A. Nepveu
Transgenic Mice Expressing the p75 CCAAT-Displacement Protein/Cut Homeobox Isoform Develop a Myeloproliferative Disease-Like Myeloid Leukemia
Cancer Res., October 1, 2006; 66(19): 9492 - 9501.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
E. S. W. Ngan, Z.-Q. Ma, S. S. Chua, F. J. DeMayo, and S. Y. Tsai
Inducible expression of FGF-3 in mouse mammary gland
PNAS, August 20, 2002; 99(17): 11187 - 11192.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Antoine, K. Reimers, C. Dickson, and P. Kiefer
Fibroblast Growth Factor 3, a Protein with Dual Subcellular Localization, Is Targeted to the Nucleus and Nucleolus by the Concerted Action of Two Nuclear Localization Signals and a Nucleolar Retention Signal
J. Biol. Chem., November 21, 1997; 272(47): 29475 - 29481.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
D Jackson, J Bresnick, I Rosewell, T Crafton, R Poulsom, G Stamp, and C Dickson
Fibroblast growth factor receptor signalling has a role in lobuloalveolar development of the mammary gland
J. Cell Sci., January 6, 1997; 110(11): 1261 - 1268.
[Abstract] [PDF]


Home page
J. Biol. Chem.Home page
M. Mathieu, E. Chatelain, D. Ornitz, J. Bresnick, I. Mason, P. Kiefer, and C. Dickson
Receptor Binding and Mitogenic Properties of Mouse Fibroblast Growth Factor 3
J. Biol. Chem., October 13, 1995; 270(41): 24197 - 24203.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Mathieu, P. Kiefer, I. Mason, and C. Dickson
Fibroblast Growth Factor (FGF) 3 from Xenopus laevis (XFGF3) Binds with High Affinity to FGF Receptor 2
J. Biol. Chem., March 24, 1995; 270(12): 6779 - 6787.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.